Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Pancreatic cancer

Cooperation

Nature Reviews Cancer volume 12, page 374 (2012)Cite this article

Subjects

Access through your institution
Buy or subscribe

This paper used the Sleeping Beauty transposon insertional mutagenesis system to identify genes that accelerate the development of KrasG12D-induced pancreatic ductal adenocarcinoma (PDA) in mice. In more than 50% of the tumours the Usp9x gene, which encodes a deubiquitylase, was inactivated. Analyses of human PDA samples indicated that low USP9X mRNA and protein levels correlate with a poor prognosis. Interestingly, treatment of human PDA cell lines with chromatin-modifying drugs, such as 5-aza-2′-deoxycytidine, increased USP9X expression, suggesting that epigenetic therapies might be appropriate for some patients with PDA.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Pérez-Mancera, P. A. et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 29 Apr 2012 (doi:10.1038/nature11114)

Download references

Authors
  1. Nicola McCarthy
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCarthy, N. Cooperation. Nat Rev Cancer 12, 374 (2012). https://doi.org/10.1038/nrc3296

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrc3296

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer